PILHLE-001: neoadjuvant pyrotinib combined with chemotherapy in HR-positive, HER2-low (IHC 2+/FISH-negative) early breast cancer

被引：0
|
作者：
Gong, Chang
Xia, Yuan
Zhu, Yingying
Yang, Yaping
Yang, Wenqian
Chow, Louis W. C.
Ling, Li
Zeng, Yunjie
Zhong, Jiajie
Cheng, Ziliang
Shen, Jun
Lin, Qun
Zeng, Yinduo
Liu, Qiang
Song, Erwei
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO1-28-04
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO1-28-04
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study
    Lu Liu
    Mingzhi Zhu
    Yanyan Wang
    Muhan Li
    Yuanting Gu
    World Journal of Surgical Oncology, 21
  • [42] Clinical efficacy of pyrotinib combined with chemotherapy for neoadjuvant treatment in HER2-positive breast cancer: a single-center study
    Wei, Benkai
    Yan, Huanhuan
    Li, Fan
    Shen, Jun
    ANTI-CANCER DRUGS, 2025, 36 (04) : 347 - 354
  • [43] Analyzing Neoadjuvant Chemotherapy Effects in HER2-Low Breast Cancer: Real World Data
    Antonini, Marcelo
    Mattar, Andre
    Richter, Fernanda G.
    Ramos, Marcellus N.
    Teixeira, Marina D.
    Pantarotto, Nathalia N.
    Matta, Nadia F.
    Amorim, Andressa G.
    Pinheiro, Denise J.
    Lopes, Reginaldo C.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (05)
  • [44] Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy according to HER2-low status
    Raghavendra, A. S.
    Zakon, D. B.
    Jin, Q.
    Strahan, A.
    Grimm, M.
    Hughes, M. E.
    Cherian, M.
    Vincuilla, J.
    Parker, T.
    Tarantino, P.
    Mittendorf, E. A.
    King, T. A.
    Valero, V.
    Tripathy, D.
    Tolaney, S. M.
    Tayob, N.
    Lin, N. U.
    Stover, D. G.
    Barcenas, C. H.
    Garrido-Castro, A. C.
    ESMO OPEN, 2024, 9 (11)
  • [45] Predictive factors for outcome in HER2-low breast cancer patients after neoadjuvant chemotherapy
    Shao, Yingbo
    Guan, Huijuan
    Luo, Zhifen
    Yu, Yang
    He, Yaning
    Chen, Qi
    Liu, Chaojun
    Zhu, Fangyuan
    Liu, Hui
    FRONTIERS IN ONCOLOGY, 2025, 15
  • [46] Neoadjuvant tucidinostat combined with chemotherapy for hormone receptor-positive, HER2-negative breast cancer
    Niu, Nan
    Xue, Jinqi
    Qiu, Fang
    Chen, Guanglei
    Gu, Xi
    He, Guijin
    Cao, Shuo
    Yu, Xiaopeng
    Xu, Yongqing
    Yin, Jianqiao
    Han, Sijia
    Han, Ye
    Tang, Meiyue
    Zhao, Yafei
    Zheng, Ran
    Zheng, Xinyu
    Xu, Hong
    Liu, Caigang
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [47] Neoadjuvant chemotherapy in HER2-positive and triple-negative breast cancer
    Goncalves, Anthony
    BULLETIN DU CANCER, 2016, 103 (06) : S76 - S89
  • [48] Assessing the potential cost-effectiveness of retesting IHC0, IHC1-positive, or FISH-negative early-stage breast cancer patients for HER2 status
    Garrison, L. P.
    Lalla, D.
    Brammer, M. G.
    Wang, B.
    Babigumira, J.
    Perez, E. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [49] HER2-low status may predict poor neoadjuvant chemotherapy response in HR-negative breast cancer: a real-world multicenter study
    Xu, Weiwei
    Jiang, Yunshan
    Xu, Lingyun
    Li, Changwen
    Wang, Ji
    Liu, Zhao
    Xue, Dandan
    Gu, Yanlin
    Zhong, Zhaoyun
    He, Shiqing
    Wang, Shui
    Zhou, Wenbin
    Pan, Hong
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 53 (06) : 463 - 471
  • [50] The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status
    Horisawa, Nanae
    Adachi, Yayoi
    Takatsuka, Daiki
    Nozawa, Kazuki
    Endo, Yuka
    Ozaki, Yuri
    Sugino, Kayoko
    Kataoka, Ayumi
    Kotani, Haruru
    Yoshimura, Akiyo
    Hattori, Masaya
    Sawaki, Masataka
    Iwata, Hiroji
    BREAST CANCER, 2022, 29 (02) : 234 - 241
12345